Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
Am J Med. 2023 Sep;136(9):927-936.e3. doi: 10.1016/j.amjmed.2023.05.013. Epub 2023 May 27.
Anticoagulants often cause adverse drug events (ADEs), comprised of medication errors and adverse drug reactions, in patients. Our study objective was to determine the clinical characteristics, types, severity, cause, and outcomes of anticoagulation-associated ADEs from 2015-2020 (a contemporary period following implementation of an electronic health record, infusion device technology, and anticoagulant dosing nomograms) and to compare them with those of a historical period (2004-2009).
We reviewed all anticoagulant-associated ADEs reported as part of our hospital-wide safety system. Reviewers classified type, severity, root cause, and outcomes for each ADE according to standard definitions. Reviewers also assessed events for patient harm. Patients were followed up to 30 days after the event.
Despite implementation of enhanced patient safety technology and procedure, ADEs increased in the contemporary period. In the contemporary period, we found 925 patients who had 984 anticoagulation-associated ADEs, including 811 isolated medication errors (82.4%); 13 isolated adverse drug reactions (1.4%); and 160 combined medication errors, adverse drug reactions, or both (16.2%). Unfractionated heparin was the most frequent ADE-related anticoagulant (77.7%, contemporary period vs 58.3%, historical period). The most frequent anticoagulation-associated medication error in the contemporary period was wrong rate or frequency of administration (26.1%, n = 253), with the most frequent root cause being prescribing errors (21.3%, n = 207). The type, root cause, and harm from ADEs were similar between periods.
We found that anticoagulation-associated ADEs occurred despite advances in patient safety technologies and practices. Events were common, suggesting marginal improvements in anticoagulant safety over time and ample opportunities for improvement.
抗凝剂常导致患者发生药物不良事件(ADE),包括用药错误和药物不良反应。本研究旨在比较 2015-2020 年(电子病历、输液装置技术和抗凝剂剂量图表实施后的当代时期)与历史时期(2004-2009 年)抗凝相关 ADE 的临床特征、类型、严重程度、原因和结局,并评估这些事件对患者的伤害。
我们回顾了作为医院范围内安全系统一部分报告的所有抗凝相关 ADE。审查员根据标准定义对每种 ADE 的类型、严重程度、根本原因和结局进行分类。审查员还评估了事件对患者的伤害。患者在事件发生后 30 天内进行随访。
尽管实施了增强的患者安全技术和程序,但在当代时期 ADE 增加了。在当代时期,我们发现 925 名患者发生了 984 例抗凝相关 ADE,包括 811 例孤立的用药错误(82.4%);13 例孤立的药物不良反应(1.4%);以及 160 例联合用药错误、药物不良反应或两者兼有(16.2%)。未分级肝素是最常见的与 ADE 相关的抗凝剂(77.7%,当代时期与 58.3%,历史时期)。当代时期最常见的抗凝相关用药错误是给药率或频率错误(26.1%,n=253),最常见的根本原因是处方错误(21.3%,n=207)。两个时期 ADE 的类型、根本原因和伤害相似。
尽管患者安全技术和实践取得了进步,但我们发现仍发生抗凝相关 ADE。事件很常见,表明随着时间的推移,抗凝安全性略有改善,但仍有很大的改进空间。